184 related articles for article (PubMed ID: 25239826)
1. In vitro and in vivo characterization of the actin polymerizing compound chondramide as an angiogenic inhibitor.
Menhofer MH; Bartel D; Liebl J; Kubisch R; Busse J; Wagner E; Müller R; Vollmar AM; Zahler S
Cardiovasc Res; 2014 Nov; 104(2):303-14. PubMed ID: 25239826
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
3. Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo.
Kretzschmann VK; Gellrich D; Ullrich A; Zahler S; Vollmar AM; Kazmaier U; Fürst R
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):294-303. PubMed ID: 24285578
[TBL] [Abstract][Full Text] [Related]
4. The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility.
Menhofer MH; Kubisch R; Schreiner L; Zorn M; Foerster F; Mueller R; Raedler JO; Wagner E; Vollmar AM; Zahler S
PLoS One; 2014; 9(11):e112542. PubMed ID: 25391145
[TBL] [Abstract][Full Text] [Related]
5. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
[TBL] [Abstract][Full Text] [Related]
6. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway.
Jiang WG; Ye L; Ji K; Frewer N; Ji J; Mason MD
Int J Oncol; 2012 Nov; 41(5):1635-42. PubMed ID: 22971748
[TBL] [Abstract][Full Text] [Related]
8. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of novel integrin-targeting peptides on angiogenesis activity in HUVEC cells in vitro.
Liu Y; Li Y; Xu Y
Cell Biochem Funct; 2011 Jul; 29(5):429-35. PubMed ID: 21590697
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.
Al-Salahi OS; Kit-Lam C; Majid AM; Al-Suede FS; Mohammed Saghir SA; Abdullah WZ; Ahamed MB; Yusoff NM
Microvasc Res; 2013 Nov; 90():30-9. PubMed ID: 23899415
[TBL] [Abstract][Full Text] [Related]
11. Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ.
Foerster F; Braig S; Moser C; Kubisch R; Busse J; Wagner E; Schmoeckel E; Mayr D; Schmitt S; Huettel S; Zischka H; Mueller R; Vollmar AM
Cell Death Dis; 2014 Aug; 5(8):e1398. PubMed ID: 25165884
[TBL] [Abstract][Full Text] [Related]
12. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
[TBL] [Abstract][Full Text] [Related]
13. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton.
Bijman MN; van Nieuw Amerongen GP; Laurens N; van Hinsbergh VW; Boven E
Mol Cancer Ther; 2006 Sep; 5(9):2348-57. PubMed ID: 16985069
[TBL] [Abstract][Full Text] [Related]
14. Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion.
Nguyen MP; Lee D; Lee SH; Lee HE; Lee HY; Lee YM
Oncotarget; 2015 Jun; 6(18):16588-600. PubMed ID: 26078334
[TBL] [Abstract][Full Text] [Related]
15. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth.
Lai KC; Hsu SC; Yang JS; Yu CC; Lein JC; Chung JG
J Cell Mol Med; 2015 Feb; 19(2):474-84. PubMed ID: 25403643
[TBL] [Abstract][Full Text] [Related]
16. Vascular disrupting activity of combretastatin analogues.
Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
Zhong ZF; Hoi PM; Wu GS; Xu ZT; Tan W; Chen XP; Cui L; Wu T; Wang YT
J Ethnopharmacol; 2012 Jun; 141(2):721-7. PubMed ID: 21911050
[TBL] [Abstract][Full Text] [Related]
18. Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activatio.
Wang Y; Wang B; Guerram M; Sun L; Shi W; Tian C; Zhu X; Jiang Z; Zhang L
Oncotarget; 2015 Oct; 6(30):29497-512. PubMed ID: 26470595
[TBL] [Abstract][Full Text] [Related]
19. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
Ren X; Dai M; Lin LP; Li PK; Ding J
Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
